Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
Active, not recruiting · NCT07213583 · Registry updated 2026-10-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Active, not recruiting | Phase 2 | 2026-10-07 | NCT07213583 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 48 |
| Neurimmune AG | 1 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| CHU De Rennes - Hôpital Pontchaillou | Rennes | France | 8 |
| CHU Toulouse - Hôpital Rangueil | Toulouse | France | 1 |
| Hospital Universitario Puerta de Hierro Majadahonda | Majadahonda | Spain | 17 |
| Hôpital Henri Mondor | Créteil | France | 16 |
| University Medical Center Groningen | Groningen | Netherlands | 7 |
| Universitätsklinikum Heidelberg | Heidelberg | Germany | 47 |